Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis

This study has been completed.
Sponsor:
Information provided by:
Juravinski Cancer Centre Foundation
ClinicalTrials.gov Identifier:
NCT00814359
First received: December 23, 2008
Last updated: January 19, 2011
Last verified: May 2009

December 23, 2008
January 19, 2011
May 2009
September 2010   (final data collection date for primary outcome measure)
The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks. [ Time Frame: Baseline to 6 weeks after the initiation of radiotherapy. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00814359 on ClinicalTrials.gov Archive Site
  • The severity of patient-reported symptoms of mucositis throughout the course radiotherapy as determined by the area under the curve for mean change in OMWQ-HN scores from baseline. [ Time Frame: Baseline to 10 weeks after initiating radiotherapy. ] [ Designated as safety issue: No ]
  • Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy. [ Time Frame: 4 weeks after initiating radiotherapy ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis
A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.

Radiation treatment is very effective for treating cancers of the head and neck, however, during the course of treatment, it is common for patients to experience soreness of their mouth and throat due to the radiation. When radiation causes inflammation of the inside of the mouth, it is called 'mucositis'. There are several mouthwashes that are commonly used to prevent and treat mucositis, but none of these have been shown to be superior to another. This study is being conducted to see if using a combination of magic mouthwash and sucralfate is better than using a single mouthwash called benzydamine at decreasing the burden of mucositis.

Sixty patients with head and neck cancer being treated with 6 or more weeks of radiotherapy, will be randomly assigned to receive either a combination of magic mouthwash (diphenhydramine, dexamethasone and nystatin) plus sucralfate or benzydamine. Patients randomized to receive magic mouthwash plus sucralfate will rinse first with 5ml of the magic mouthwash for 2 minutes then swallow, followed by rinsing with 5ml of the 1g/5ml sucralfate for 2 minutes before swallowing, 4 times daily. Patients randomized to receive 0.15% benzydamine HCl will be instructed to rinse with 15ml of the solution for 2 minutes before expectorating, 4 times daily. Patients will start the mouthwash regimens prior to the initiation of radiotherapy, and stop 2 weeks after the completion of radiotherapy.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Head and Neck Cancer
  • Mucositis
  • Drug: Combination of Magic Mouthwash Plus Sucralfate

    Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.

    The concentration of the sucralfate suspension will be 1g/5ml.

    Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.

    Other Names:
    • Mucositis Mouthwash
    • Sulcrate
  • Drug: 0.15% Benzydamine HCl
    Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
    Other Name: Tantum
  • Experimental: Magic Mouthwash Plus Sucralfate
    Intervention: Drug: Combination of Magic Mouthwash Plus Sucralfate
  • Active Comparator: Benzydamine HCl
    Intervention: Drug: 0.15% Benzydamine HCl

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
67
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven squamous cell carcinoma of the head and neck.
  • Receiving 6 or more weeks of external beam radiotherapy to a treatment volume that includes mucosal surfaces of the head and neck.

Exclusion Criteria:

  • Age less than 18 years
  • ECOG Performance Score 2 or higher
  • Patient is unable to understand the protocol and/or unable to provide informed consent
  • Patient is unable or unwilling to complete the questionnaires which are written in English.
  • Prior radiation to the head and neck region that would result in overlap of fields for the current study.
  • Plan to receive a radiation treatment volume that only includes the larynx and or hypopharynx with no planned treatment of locoregional lymph nodes.
  • Plan to receive a concurrent chemotherapy agent other than cisplatin.
  • Plan to receive other investigational agents (eg. panitumumab).
  • Investigational agent of any kind within 30 days prior to randomization.
  • Concurrent administration of any other experimental intervention given for the purpose of preventing oral mucositis.
  • History of allergic or hypersensitivity reactions to any of the possible agents to be administered in the study.
  • Patients who are pregnant or lactating.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00814359
MUCOSA-PROTECT
No
Dr. Joda Kuk, Principal Investigator, Juravinski Cancer Centre
Juravinski Cancer Centre Foundation
Not Provided
Principal Investigator: Joda Kuk, MD Juravinski Cancer Centre
Juravinski Cancer Centre Foundation
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP